Abstracts tagged "drug treatment and rheumatoid arthritis (RA)"

Abstract Number: 2378 • 2017 ACR/ARHP Annual Meeting
Body Mass Index and Persistence of Conventional Dmards and TNF Inhibitors in Rheumatoid Arthritis
Caroline McCulley¹, Ted R. Mikuls², Jennifer Barton³, Grant Cannon⁴, Brian C. Sauer, PhD⁵, Liron Caplan⁶, Bryant R. England⁷, Chia-Chen Teng⁸ and Joshua Baker⁹, ¹Rheumatology, Oregon Health & Science University, Portland, OR, ²Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³VA Portland Health Care System, Portland, OR, ⁴Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁵Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁶Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁷Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁸Rheumatology, University of Utah, Salt Lake City, UT, ⁹Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Low body mass index (BMI) is associated with more destructive disease in rheumatoid arthritis (RA). Paradoxically, obese patients have been shown in studies to…
Abstract Number: 2172 • 2016 ACR/ARHP Annual Meeting
Impact of Biologic and Non-Biologic Treatment on the Incidence of Traditional Cardiovascular Risk Factors Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis
Helga Radner¹, Tamara Lesperance², Neil A. Accortt³ and Daniel H. Solomon⁴, ¹Rheumatology, Medical University of Vienna, Vienna, Austria, ²DOCS Global, Inc., North Wales, PA, ³Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Studies have suggested that the chronic inflammatory nature of rheumatic conditions (rheumatoid arthritis (RA) and psoriatic arthritis (PsA)) as well as psoriasis (PsO) may…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].